Sanchari Basu Mallik

Sanchari Basu Mallik

Auto-generated profile, based on publicly available information

Sanchari Basu Mallik

School of Pharmacy and Medical Sciences, Griffith University, Queensland, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
SMSanchari Basu Mallik
Sanchari Basu Mallik
BJB.S. Jayashree
B.S. Jayashree
RSRekha R. Shenoy
Rekha R. Shenoy

1 October 2016 in Neuroscience Letters
Verified
Journal Article
Closed access
SMSanchari Basu Mallik
Sanchari Basu Mallik
JMJayesh Mudgal
Jayesh Mudgal
MNMadhavan Nampoothiri
Madhavan Nampoothiri
Susan HallSusan Hall
Susan Hall
SDShailendra Anoopkumar - Dukie
Shailendra Anoopkumar - Dukie
DADevinder Arora
Devinder Arora

1 August 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JFJessica Fernandes
Jessica Fernandes
MGM. Vivek Ghate
M. Vivek Ghate
SMSanchari Basu Mallik
Sanchari Basu Mallik
SLShaila A. Lewis
Shaila A. Lewis

8 January 2018 in Toxicology Mechanisms and Methods
Verified
Journal Article
Closed access
JFJoylee Fernandes
Joylee Fernandes
JMJayesh Mudgal
Jayesh Mudgal
CRChamallamudi Mallikarjuna Rao
Chamallamudi Mallikarjuna Rao
DADevinder Arora
Devinder Arora
SMSanchari Basu Mallik
Sanchari Basu Mallik
MGMADHAVAN NAMPOOTHIRI G
MADHAVAN NAMPOOTHIRI G
Neuroinflammation plays an important role in the pathophysiology of Alzheimer’s disease. Neurokinin substance P is a key mediator which modulates neuroinflammation through neurokinin receptor. Involvement of substance P in Alzheimer’s disease is still plausible and various controversies exist in this hypothesis. Preventing the deleterious effects of substance P using N-acetyl-L-tryptophan, a substance P antagonist could be a promising therapeutic strategy. This study was aimed to evaluate the effect of N-acetyl-L-tryptophan on aluminum induced spatial memory alterations in rats. Memory impairment was induced using aluminum chloride (AlCl3) at a dose of 10 mg/kg for 42 d. After induction of dementia, rats were exposed to 30 and 50 mg/kg of N-acetyl-L-tryptophan for 28 d. Spatial memory alterations were measured using Morris water maze. Acetylcholinesterase activity and antioxidant enzyme glutathione level were assessed in hippocampus, frontal cortex and striatum. The higher dose of N-acetyl-L-tryptophan (50 mg/kg) significantly improved the aluminum induced memory alterations. N-acetyl-L-tryptophan exposure resulted in significant increase in acetylcholinesterase activity and glutathione level in hippocampus. The neuroprotective effect of N-acetyl-L-tryptophan could be due to its ability to block substance P mediated neuroinflammation, reduction in oxidative stress and anti-apoptotic properties. To conclude, N-acetyl-L-tryptophan may be considered as a novel neuroprotective therapy in Alzheimer’s disease.

5 April 2021 in Nutritional Neuroscience
Verified
Journal Article
Closed access
SMSanchari Basu Mallik
Sanchari Basu Mallik
JMJayesh Mudgal
Jayesh Mudgal
Susan HallSusan Hall
Susan Hall
MKManas Kinra
Manas Kinra
GGGary D. Grant
Gary D. Grant
DADevinder Arora
Devinder Arora
Objective: Caffeine (CAF) is one of the most commonly consumed nutritional stimulant in beverages. Interestingly, CAF produces varied effects in a dose-dependent manner, and that makes it one of the most controversial nutritional ingredients. Various studies have linked CAF consumption and reduced risk of depressive disorders. The aim of this study was to investigate the effect of CAF on lipopolysaccharide (LPS)-induced neuroinflammation and depressive-like behaviour. Methods: C57BL/6J male mice were divided into four groups consisting of saline (SAL), LPS, CAF and Imipramine (IMI). Animals were pretreated orally with CAF (10 mg/kg) and IMI (10 mg/kg) for 14 days once daily and all groups except SAL were challenged with LPS (0.83 mg/kg) intraperitoneally on day 14. Results: LPS produced a biphasic behavioural response with a significantly high immobility time and weight loss after 24 h. The brain cytokines (TNF-α, IL-6, IL-1β, and IFN-γ) levels were remarkably high, along with increased lipid peroxidation and reduced Brain Derived Neurotrophic Factor (BDNF). These biochemical and behavioural changes were significantly alleviated by CAF and IMI chronic treatment. Conclusion: The results of this study implicate that mild-moderate consumption of CAF could impart anti-inflammatory properties under neuroinflammatory conditions by modulating the cytokine and neurotrophic mechanisms.

25 July 2023 in Metabolic Brain Disease
Verified
Journal Article
Open access
PDF file
SMSanchari Basu Mallik
Sanchari Basu Mallik
JMJayesh Mudgal
Jayesh Mudgal
MKManas Kinra
Manas Kinra
Susan HallSusan Hall
Susan Hall
GGGary Grant
Gary Grant
DADevinder Arora
Devinder Arora
Objective: Ferulic acid (FA) is a common food ingredient that is abundantly present in various routinely consumed food and beverages. Like many cinnamic acid derivatives, FA produces wide-ranging effects in a dose-dependent manner and various studies link FA consumption with reduced risk of depressive disorders. The aim of this study was to exploit the neuroprotective mechanisms of FA including indoleamine 2,3-dioxygenase (IDO), brain-derived neurotrophic factor (BDNF), and other pro-inflammatory cytokines by employing lipopolysaccharide (LPS)-induced depressive-like behaviour model. Methods: C57BL/6J male mice were divided into 4 groups consisting of saline (SAL), LPS, FA and Imipramine (IMI). Animals were pretreated orally with FA (10 mg/kg) and IMI (10 mg/kg) for 21 days once daily and all groups except SAL were challenged with LPS (0.83 mg/kg) intraperitoneally on day 21. Results: LPS administration produced a biphasic change in the behaviour of the animals where the animals lost a significant weight and express high immobility time at 24 h. Proinflammatory cytokines including, TNF-α, IL-6, IL-1β, and IFN-γ were significantly increased along with increased lipid peroxidation and reduced BDNF. Furthermore, the increased kynurenine to tryptophan ratio was indicative of elevated IDO activity. Conclusion: The results of this study emphasise that low dose of FA is effective in attenuating depressive-like behaviour by modulating IDO, BDNF and reducing neuroinflammation.